Alamar Biosciences Inc. Reports Robust Third‑Quarter 2026 Performance and Expands Strategic Collaborations
Alamar Biosciences Inc. (NASDAQ: ALMR), a specialist in precision proteomics, announced its third‑quarter 2026 financial results on November 3, 2026. The company’s revenue for the quarter reached $33.5 million, representing a 68 % year‑over‑year increase. The growth was driven primarily by expanded participation in the UK Biobank programme and new scientific partnerships that broaden the application of Alamar’s flagship NULISA™ platform.
Financial Highlights
| Item | 2026 Q3 | 2025 Q3 |
|---|---|---|
| Total Revenue | $33.5 M | $20.0 M |
| Revenue Growth | +68 % | — |
| Net Income | (loss) | — |
| Cash Position | — | — |
The company has also revised its 2026 revenue guidance upward, reflecting stronger demand for its proteomic assays across a range of therapeutic areas.
UK Biobank Collaboration
A key driver of the quarter’s success is Alamar’s partnership with Nightingale Health Plc to launch the UK Biobank vanguard study, a large‑scale effort that will profile 80,000 samples for neurodegenerative disease research. The study focuses on blood‑based biomarkers relevant to Parkinson’s disease, Alzheimer’s disease, and other rare dementias. By providing comprehensive proteomic signatures, the project aims to identify early disease markers, improve risk stratification, and inform prevention strategies. Alamar’s involvement underscores its commitment to applying proteomics to complex, chronic conditions.
Strategic Alliance with GlaxoSmithKline
In a separate development, Alamar announced a collaboration with GlaxoSmithKline plc (GSK) to utilize its NULISA™ platform in a multi‑organ system study. The partnership will investigate how circulating protein signatures correlate with disease progression, biological subtypes, and treatment response across respiratory, liver, kidney, neurological, and autoimmune conditions. The study is expected to generate actionable insights that can accelerate precision medicine initiatives and potentially enhance drug development pipelines.
Market Context and Outlook
Alamar’s stock closed at $28.94 on November 1, 2026, after a notable rally that lifted the price from a 52‑week low of $18.85 to a new high of $39.61 on October 5. With a market capitalization of approximately $2.12 billion, the company occupies a niche position within the health‑care sector, focusing on early disease detection rather than traditional therapeutics.
The combination of rising revenue, strengthened research collaborations, and the expansion of its proteomic platform positions Alamar to capitalize on the growing demand for biomarker‑driven diagnostics. Investors and industry observers will likely monitor the progression of the UK Biobank study and the outcomes of the GSK partnership for signals of future commercial traction.
